The economics of making a generic

Seventy percent of the generic injectable products launched in the US between July 2018 and July 2021 had not earned back their costs three years later, according to a December 2024 analysis¹ by the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE), using its middle cost estimate. Oral generics did better, though most of them had not broken even either. Forty-one percent of oral launches were in the black at the three-year mark.

Making a generic involves three numbers. A company pays a large fixed cost to win FDA approval and get a production line ready. It then pays a cost for every tablet or vial it makes. And it sells at a price set largely by how many competitors show up. When the price falls faster than the costs, products stop being made.

FDA's 2019 shortage task force⁴ named that dynamic, a "lack of incentives to produce less profitable drugs," as the first root cause of drug shortages. Federal estimates and GxRadar's price data put rough numbers on each part of that arithmetic.

The fixed cost of getting to market

The most detailed public estimate comes from a cost study prepared under contract for ASPE² and published in December 2021. For a simple immediate-release tablet with no patents in the way and a waiver from human bioequivalence testing, it estimated about $2.4 million in direct development spending over roughly 59 months. Once the chance of failure at each stage and an 8.82 percent annual cost of capital are counted, the expected cost rose to about $5.3 million, more than double the cash outlay. Drugs that need bioequivalence studies in people cost more, and the study found those studies "constitute a major portion of overall development costs."

Time is part of the bill. The same study² put FDA's first-cycle approval rate at around 20 percent and estimated that raising it to 66 percent would bring products to market about 13 months sooner, cutting expected capitalized costs by about $3.5 million across application types. For injectables, ASPE's 2024 analysis¹ used fixed-cost scenarios of about $5.9 million, $9.2 million and $12.2 million per product.

FDA's user fees sit on top of development spending. The rates for fiscal 2027, set in a July 2026 Federal Register notice³, apply from Oct. 1, 2026, through Sept. 30, 2027.

How those fees fund review is explained in GDUFA: how generic drug user fees fund FDA review, and the approval steps they pay for are in How a generic drug gets approved. Plants cost far more than applications. FDA's 2019 report⁴ said expanding or modernizing a facility that makes multiple products can take a year or more and cost more than $100 million.

The cost of each unit

Per-unit costs are harder to see from outside, so ASPE's 2024 analysis¹ borrowed published estimates of the cost of goods sold: 36 percent of revenue for oral generics and 42 percent for injectables. Sterile injectables need specialized equipment and tighter controls, and FDA's task force said most generic manufacturers "cannot afford to support redundant capacity." Some products are made under contract rather than in the application holder's own plant, as described in contract manufacturing in generics, and the ingredient itself usually comes from overseas, as described in Where generic drug ingredients come from.

Quality spending is a cost that buyers rarely see. FDA's second root cause⁴ of shortages was that the market "does not recognize and reward manufacturers for mature quality management systems." Every maker has to meet current good manufacturing practice rules, but a company that invests beyond the minimum generally cannot charge more for it.

How competition sets the price

Price is where the economics turn. ASPE's January 2025 brief⁵ on Medicare data found generic prices about 20 percent below the pre-generic level in markets with about three competitors, and 70 to 80 percent lower in markets with 10 or more, three years after first generic entry. GxRadar's analysis of CMS NADAC files⁶ through October 2026 shows where some common products have ended up. NADAC measures what retail pharmacies pay, so it includes the wholesaler's markup and sits above what the manufacturer receives.

Digoxin is the outlier. Its NADAC jumped from about 11 cents a tablet in November 2013 to $1.09 in March 2014, then drifted back down over the following years, an episode covered in The generic price spikes of 2013 to 2015. For the rest, the decline is the normal course described in the long deflation of generic prices and in Why generic prices fall as competitors enter. Full histories for 47 products are on the prices page.

Purchasing contracts add pressure. FDA's task force⁴ said prevalent contracting practices "often constrain the ability of manufacturers to raise their prices, while leaving them open to price challenges from competitors," and that some manufacturers end up in "a race to the bottom," in some cases selling a drug at or below its cost to manufacture. Many markets are also small. Summarizing academic research, the report said median quarterly sales for a generic molecule in one dosage form were just over $300,000 in the third quarter of 2016.

Break-even, profit and exit

ASPE's 2024 return-on-investment analysis¹⁰ put those pieces together for products launched from July 2018 to July 2021, tracking each for 36 months.

Averages flatter the market. ASPE found net profit heavily skewed, with a handful of big winners pulling the average return up while most launches were still underwater. For the median injectable launch, the first three years ended in a loss.

When a product stops paying, FDA's 2019 report⁴ said, management "may discontinue production or make minimal investments." With little spare capacity, a manufacturer may also move a line to a more profitable drug that runs on the same equipment, though some told FDA they keep making unprofitable drugs that are in shortage or fill a gap in their portfolio. ASPE's January 2025 shortage data brief⁷ described the long arc. Generic entry drives prices down, which "gradually erodes profits for all market participants," and "some drug suppliers eventually exit."

Exits show up in FDA's shortage database. On Oct. 30, 2026, it listed 161 drug entries with the status "To Be Discontinued," a category explained in our piece on discontinuation entries, 124 of them first posted in 2026, according to GxRadar's analysis of openFDA shortage data⁸. The list mixes brand and generic products and gives no business reason, and a discontinuation does not always cause a shortage. Current listings are on the shortage tracker. Why exits hit injectables hardest is in Why sterile injectables dominate shortage lists, and the competitive end state is in Why some generics have only one maker.

What federal proposals target

HHS's 2024 white paper on shortages⁹ proposed two programs aimed at the price side of the problem, focused on generic sterile injectables used in hospitals. A Manufacturer Resiliency Assessment Program would measure manufacturers on supply chain resilience, and a Hospital Resilient Supply Program would use incentives or penalties to steer hospital purchasing toward more resilient suppliers. HHS said lasting fixes would require additional statutory authorities and funding. On the cost side, the current GDUFA fee schedule runs through Sept. 30, 2027.